ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections

Phase 2INNA-051Positive

AI Analysis

Summary

ENA Respiratory has initiated dosing of participants in Part B of its Phase IIa community study of INNA-051, a host defence enhancer for preventing complications from respiratory viral infections in at-risk populations.

Clinical Trial Data

Phase

IIa

Outcome Details

First participants dosed in Part B of Phase IIa community study

Importance:5/10

Sentiment:

0.30

clinical trialPhase 2respiratoryviral infectionshost defence

Related Companies

$CHCT $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 15, 2026 8:00 AM

Read Original